(Stroke. 1995;26:795-800.)
© 1995 American Heart Association, Inc.
Articles |
Plasma Homocysteine in the Acute and Convalescent Phases After Stroke
Presented at the Third European Stroke Conference, Stockholm, Sweden, May 26-28, 1994.
From the Departments of Neurology (A.L., B.N., B.B.J.) and Clinical Chemistry (B.H., A.A.), University Hospital, Lund; and the Department of Internal Medicine (L.B.), County Hospital, Kalmar, Sweden.
Correspondence to Arne Lindgren, MD, Department of Neurology, University Hospital, S-221 85 Lund, Sweden.
Background and Purpose Stroke patients frequently manifest moderate hyperhomocysteinemia. In most published studies, plasma homocysteine was measured at least 1 month after stroke (or the interval was not reported). To determine whether plasma homocysteine concentrations change in the acute phase, we compared acute-phase values with both convalescent-phase and control values.
Methods Plasma homocysteine concentrations were measured in the acute phase (mean, 2 days after stroke onset) in 162 first-ever stroke patients aged 50 years or more (median, 75 years) and again at a median interval of 583 days (range, 460 to 645 days) after stroke onset in a subgroup of 17 patients, with values for 60 age-matched subjects serving as controls. Twenty of the control subjects were reexamined 2 to 3 years after their initial examination.
Results The median plasma homocysteine concentration was 13.4 µmol/L in the patient group compared with 13.8 µmol/L for control subjects (NS, Mann-Whitney U test) and increased from 11.4 µmol/L in the acute phase to 14.5 µmol/L in the convalescent phase in the subgroup of patients examined twice (P<.01, Wilcoxon signed rank test). In the 20 reexamined control subjects, no significant change over time in plasma homocysteine concentration was found.
Conclusions The post–acute-phase increase in plasma homocysteine may explain why higher values were obtained for stroke patients than for control subjects in previous studies. Possible reasons for the variation in plasma homocysteine concentrations over time are (1) an acute-phase reduction secondary to a decrease in plasma albumin and (2) an increase in plasma homocysteine during the convalescent phase due to modified vitamin intake and/or lifestyle. The timing of plasma homocysteine measurements relative to stroke onset is a factor to be considered in the interpretation of results.
Key Words: cerebral infarction • homocysteine • risk factors • stroke onset
This article has been cited by other articles:
 |
|
 |
|
  G. Saposnik, J. G. Ray, P. Sheridan, M. McQueen, E. Lonn, and the HOPE 2 Investigators Homocysteine-Lowering Therapy and Stroke Risk, Severity, and Disability: Additional Findings From the HOPE 2 Trial Stroke, April 1, 2009; 40(4): 1365 - 1372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J Moat Plasma total homocysteine: instigator or indicator of cardiovascular disease? Ann Clin Biochem, July 1, 2008; 45(4): 345 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Gori, A. M. Corsi, S. Fedi, A. Gazzini, F. Sofi, B. Bartali, S. Bandinelli, G. F. Gensini, R. Abbate, and L. Ferrucci A proinflammatory state is associated with hyperhomocysteinemia in the elderly Am. J. Clinical Nutrition, August 1, 2005; 82(2): 335 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sato, Y. Honda, J. Iwamoto, T. Kanoko, and K. Satoh Effect of Folate and Mecobalamin on Hip Fractures in Patients With Stroke: A Randomized Controlled Trial JAMA, March 2, 2005; 293(9): 1082 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Martinez-Berriotxoa, G Ruiz-Irastorza, M-V Egurbide, M Rueda, and C Aguirre Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus Lupus, December 1, 2004; 13(12): 927 - 933. [Abstract] [PDF]
|
|
|
|
 |
|
 S. J. Moat, S. N. Doshi, D. Lang, I. F. W. McDowell, M. J. Lewis, and J. Goodfellow Treatment of coronary heart disease with folic acid: is there a future? Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H1 - H7. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Iso, Y. Moriyama, S. Sato, A. Kitamura, T. Tanigawa, K. Yamagishi, H. Imano, T. Ohira, T. Okamura, Y. Naito, et al. Serum Total Homocysteine Concentrations and Risk of Stroke and Its Subtypes in Japanese Circulation, June 8, 2004; 109(22): 2766 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin, et al. Facts and Recommendations about Total Homocysteine Determinations: An Expert Opinion Clin. Chem., January 1, 2004; 50(1): 3 - 32. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hassan, B. J. Hunt, M. O'Sullivan, R. Bell, R. D'Souza, S. Jeffery, J. M. Bamford, and H. S. Markus Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction Brain, January 1, 2004; 127(1): 212 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Matetzky, D. Freimark, S. Ben-Ami, I. Goldenberg, J. Leor, R. Doolman, I. Novikov, M. Eldar, and H. Hod Association of Elevated Homocysteine Levels With a Higher Risk of Recurrent Coronary Events and Mortality in Patients With Acute Myocardial Infarction Arch Intern Med, September 8, 2003; 163(16): 1933 - 1937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bosy-Westphal, M. Ruschmeyer, N. Czech, G. Oehler, H. Hinrichsen, M. Plauth, E. Lotterer, W. Fleig, and M. J. Muller Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation Am. J. Clinical Nutrition, May 1, 2003; 77(5): 1269 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Boysen, T. Brander, H. Christensen, R. Gideon, and T. Truelsen Homocysteine and Risk of Recurrent Stroke Stroke, May 1, 2003; 34(5): 1258 - 1261. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ay, E. M. Arsava, S. L. Tokgozoglu, N. Ozer, and O. Saribas Hyperhomocysteinemia Is Associated With the Presence of Left Atrial Thrombus in Stroke Patients With Nonvalvular Atrial Fibrillation Stroke, April 1, 2003; 34(4): 909 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Homocysteine Studies Collaboration Homocysteine and Risk of Ischemic Heart Disease and Stroke: A Meta-analysis JAMA, October 23, 2002; 288(16): 2015 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Kelly, J. Rosand, J. P. Kistler, V. E. Shih, S. Silveira, A. Plomaritoglou, and K. L. Furie Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: Results of a meta-analysis Neurology, August 27, 2002; 59(4): 529 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C.-K. Tan, N. Venketasubramanian, S.-M. Saw, and H. T.-L. Tjia Hyperhomocyst(e)inemia and Risk of Ischemic Stroke Among Young Asian Adults Stroke, August 1, 2002; 33(8): 1956 - 1962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pezzini, E. Del Zotto, S. Archetti, R. Negrini, P. Bani, A. Albertini, M. Grassi, D. Assanelli, R. Gasparotti, L. A. Vignolo, et al. Plasma Homocysteine Concentration, C677T MTHFR Genotype, and 844ins68bp CBS Genotype in Young Adults With Spontaneous Cervical Artery Dissection and Atherothrombotic Stroke Stroke, March 1, 2002; 33(3): 664 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. J. Howard, E. G. Sides, G. C. Newman, S. N. Cohen, G. Howard, M. R. Malinow, and J. F. Toole Changes in Plasma Homocyst(e)ine in the Acute Phase After Stroke Stroke, February 1, 2002; 33(2): 473 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. N. Chan, T. M.M. Tan, and S. J. Hurel Hyperhomocysteinemia and Macroangiopathy in Type 2 Diabetes Diabetes Care, June 1, 2001; 24(6): 1123 - 1124. [Full Text]
|
|
|
|
|
|
M. Buysschaert and M.P. Hermans Response to Chan et al.: Hyperhomocysteinemia and Macroangiopathy in Type 2 Diabetes Diabetes Care, June 1, 2001; 24(6): 1124 - 1125. [Full Text]
|
|
|
|
|
|
T. Kosokabe, K. Okumura, T. Sone, J. Kondo, H. Tsuboi, H. Mukawa, T. Tomida, T. Suzuki, H. Kamiya, H. Matsui, et al. Relation of a Common Methylenetetrahydrofolate Reductase Mutation and Plasma Homocysteine With Intimal Hyperplasia After Coronary Stenting Circulation, April 24, 2001; 103(16): 2048 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M K Al-Obaidi, P J Stubbs, R Amersey, and M I M Noble Acute and convalescent changes in plasma homocysteine concentrations in acute coronary syndromes Heart, April 1, 2001; 85(4): 380 - 384. [Abstract] [Full Text]
|
|
|
|
 |
|
 U B Fallon, P Elwood, Y Ben-Shlomo, J B Ubbink, R Greenwood, and G D. Smith Homocysteine and ischaemic stroke in men: the Caerphilly study J Epidemiol Community Health, February 1, 2001; 55(2): 91 - 96. [Abstract] [Full Text]
|
|
|
|
|
|
U B Fallon, Y Ben-Shlomo, P Elwood, J B Ubbink, and G D. Smith Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up Heart, February 1, 2001; 85(2): 153 - 158. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Meiklejohn, M. A. Vickers, R. Dijkhuisen, and M. Greaves Plasma Homocysteine Concentrations in the Acute and Convalescent Periods of Atherothrombotic Stroke Stroke, January 1, 2001; 32(1): 57 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. H. El Kossi and M. M. Zakhary Oxidative Stress in the Context of Acute Cerebrovascular Stroke Stroke, August 1, 2000; 31(8): 1889 - 1892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Barba, S. Martinez-Espinosa, E. Rodriguez-Garcia, M. Pondal, J. Vivancos, and T. Del Ser Poststroke Dementia : Clinical Features and Risk Factors Stroke, July 1, 2000; 31(7): 1494 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom, G. J. Hankey, S. S. Anand, E. Lofthouse, N. Staples, and R. I. Baker Association Between High Homocyst(e)ine and Ischemic Stroke due to Large- and Small-Artery Disease but Not Other Etiologic Subtypes of Ischemic Stroke Stroke, May 1, 2000; 31(5): 1069 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Christen, U. A. Ajani, R. J. Glynn, and C. H. Hennekens Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease: Causal or Casual? Arch Intern Med, February 28, 2000; 160(4): 422 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Fonseca, S. C. Guba, and L. M. Fink Hyperhomocysteinemia and the Endocrine System: Implications for Atherosclerosis and Thrombosis Endocr. Rev., October 1, 1999; 20(5): 738 - 759. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. D. Kark, J. Selhub, B. Adler, J. Gofin, J. H. Abramson, G. Friedman, and I. H. Rosenberg Nonfasting Plasma Total Homocysteine Level and Mortality in Middle-Aged and Elderly Men and Women in Jerusalem Ann Intern Med, September 7, 1999; 131(5): 321 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Eikelboom, E. Lonn, J. Genest Jr., G. Hankey, and S. Yusuf Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence Ann Intern Med, September 7, 1999; 131(5): 363 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kittner, W. H. Giles, R. F. Macko, J. R. Hebel, M. A. Wozniak, R. J. Wityk, P. D. Stolley, B. J. Stern, M. A. Sloan, R. Sherwin, et al. Homocyst(e)ine and Risk of Cerebral Infarction in a Biracial Population : The Stroke Prevention in Young Women Study Stroke, August 1, 1999; 30(8): 1554 - 1560. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker Evaluating Novel Cardiovascular Risk Factors: Can We Better Predict Heart Attacks? Ann Intern Med, June 1, 1999; 130(11): 933 - 937. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Ridker, J. E. Manson, J. E. Buring, J. Shih, M. Matias, and C. H. Hennekens Homocysteine and Risk of Cardiovascular Disease Among Postmenopausal Women JAMA, May 19, 1999; 281(19): 1817 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Kristensen, J. Malm, T. K. Nilsson, J. Hultdin, B. Carlberg, G. Dahlen, and T. Olsson Hyperhomocysteinemia and Hypofibrinolysis in Young Adults With Ischemic Stroke Stroke, May 1, 1999; 30(5): 974 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Malinow, A. G. Bostom, and R. M. Krauss Homocyst(e)ine, Diet, and Cardiovascular Diseases : A Statement for Healthcare Professionals From the Nutrition Committee, American Heart Association Circulation, January 12, 1999; 99(1): 178 - 182. [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Yoo, C.-S. Chung, and S.-S. Kang Relation of Plasma Homocyst(e)ine to Cerebral Infarction and Cerebral Atherosclerosis Stroke, December 1, 1998; 29(12): 2478 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Kuller and R. W. Evans Homocysteine, Vitamins, and Cardiovascular Disease Circulation, July 21, 1998; 98(3): 196 - 199. [Full Text] [PDF]
|
|
|
|
|
|
J. H. Stein and P. E. McBride Hyperhomocysteinemia and Atherosclerotic Vascular Disease: Pathophysiology, Screening, and Treatment Arch Intern Med, June 22, 1998; 158(12): 1301 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Evans, B. J. Shaten, J. D. Hempel, J. A. Cutler, and L. H. Kuller Homocyst(e)ine and Risk of Cardiovascular Disease in the Multiple Risk Factor Intervention Trial Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 1947 - 1953. [Abstract] [Full Text]
|
|
|
|
|
|
I. M. Graham, L. E. Daly, H. M. Refsum, K. Robinson, L. E. Brattstrom, P. M. Ueland, R. J. Palma-Reis, G. H. J. Boers, R. G. Sheahan, B. Israelsson, et al. Plasma Homocysteine as a Risk Factor for Vascular Disease: The European Concerted Action Project JAMA, June 11, 1997; 277(22): 1775 - 1781. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Lipton, W.-K. Kim, Y.-B. Choi, S. Kumar, D. M. D'Emilia, P. V. Rayudu, D. R. Arnelle, and J. S. Stamler Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor PNAS, May 27, 1997; 94(11): 5923 - 5928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Boushey, S. A. A. Beresford, G. S. Omenn, and A. G. Motulsky A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease: Probable Benefits of Increasing Folic Acid Intakes JAMA, October 4, 1995; 274(13): 1049 - 1057. [Abstract] [PDF]
|
|